Top 5 Drug Type | Count |
---|---|
Small molecule drug | 22 |
Target |
Mechanism NOX inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PRMT4 activators |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Protein-arginine N-methyltransferases inhibitors |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2022 |
Sponsor / Collaborator |
Start Date01 Mar 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CPP-11H ( NOX ) | Inflammation More | Discovery |
NCATS-SM7270 ( NOX ) | Inflammation More | Discovery |
GKT-136901 ( NOX1 x NOX4 ) | Inflammation More | Discovery |
EML-147 ( PRMTs ) | - | Discovery |
EML-107 | - | Discovery |